Of note, in an independent dataset of 32 poor risk AML cases [22], the phosphorylation of PHF2 at Ser705 was significantly elevated in cases sensitive to ex vivo treatment with 1 μM PF-3758309 (Fig. 8F), thus confirming the relevance of this site as a marker of PAK activity and PAKi sensitivity in an unrelated patient cohort. The gene discussed is PHF2; the disease is acute myeloid leukemia.